Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2019

Open Access 01-12-2019 | Cholangiocarcinoma | Review

Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis

Authors: Qiao Ke, Bin Wang, Nanping Lin, Lei Wang, Jingfeng Liu

Published in: World Journal of Surgical Oncology | Issue 1/2019

Login to get access

Abstract

Background

High-grade dysplasia/carcinoma in situ (HGD/CIS) of the biliary duct margin was found to not affect the prognosis of patients with extrahepatic cholangiocarcinoma by recent studies, but it has not yet reached a conclusion.

Methods

Eligible studies were searched by PubMed, PMC, MedLine, Embase, the Cochrane Library, and Web of Science, from Jan. 1, 2000 to Jun. 30, 2019, investigating the influences of surgical margin status of biliary duct on the prognosis of patients with resectable extrahepatic cholangiocarcinoma. Overall survival (OS) and local recurrence were evaluated by odds ratio (OR) with 95% confidence interval (CI).

Results

A total of 11 studies were enrolled in this meta-analysis, including 1734 patients in the R0 group, 194 patients in the HGD/CIS group, and 229 patients in the invasive carcinoma (INV) group. The pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and R0 group was 0.98 (95% CI 0.65~1.50), 1.01 (95% CI 0.73~1.41), and 0.98 (95% CI 0.72~1.34), respectively. The pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and INV group was 1.83 (95% CI 1.09~3.06), 4.52 (95% CI 2.20~9.26), and 3.74 (95% CI 2.34~5.96), respectively. Subgroup analysis of extrahepatic cholangiocarcinoma at early stage showed that the pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and R0 group was 0.54 (95% CI 0.21~1.36), 0.75 (95% CI 0.35~1.58), and 0.74 (95% CI 0.40~1.37), respectively, and the pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and INV group was 3.47 (95% CI 1.09~11.02), 9.12 (95% CI 2.98~27.93), and 9.17 (95% CI 2.95~28.55), respectively. However, the pooled OR for the incidence of local recurrence between HGD/CIS group and R0 group was 3.54 (95% CI 1.66~7.53), and the pooled OR for the incidence of local recurrence between HGD/CIS group and INV group was 0.93 (95% CI 0.50~1.74).

Conclusion

With the current data, we concluded that HGD/CIS would increase the risk of local recurrence compared with R0, although it did not affect the prognosis of patients with extrahepatic cholangiocarcinoma regardless of TNM stage. However, the conclusion needs to be furtherly confirmed.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed
2.
Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, Koshiol J. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer-Am Cancer Soc. 2019;125:1489–98.
3.
Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104–14.PubMedCrossRef
4.
Benson AB, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, et al. Guidelines insights: hepatobiliary cancers, Version 2.2019. J Natl Compr Canc Netw. 2019;17:302–10.PubMedCrossRef
5.
Franken LC, Schreuder AM, Roos E, van Dieren S, Busch OR, Besselink MG, van Gulik TM. Morbidity and mortality after major liver resection in patients with perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surgery. 2019;165:918–28.PubMedCrossRef
6.
Strijker M, Belkouz A, van der Geest LG, van Gulik TM, van Hooft JE, de Meijer VE, Haj MN, de Reuver PR, Verheij J, de Vos-Geelen J, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 2019;58:1048–55.PubMedCrossRef
7.
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer-Am Cancer Soc. 2016;122:1349–69.
8.
Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans J, Vivarelli M, Zieniewicz K, Olde DS, Groot KB. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):143–55.PubMedPubMedCentralCrossRef
9.
Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: a single-institution experience in China. World J Gastroenterol. 2016;22:2601–10.PubMedPubMedCentralCrossRef
10.
Bird N, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105:1408–16.PubMedCrossRef
11.
Chua TC, Mittal A, Arena J, Sheen A, Gill AJ, Samra JS. Resection margin influences survival after pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg. 2017;213:1072–6.PubMedCrossRef
12.
Park Y, Hwang DW, Kim JH, Hong SM, Jun SY, Lee JH, Song KB, Jun ES, Kim SC, Park KM. Prognostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection versus R0 after additional resection. J Hepatobiliary Pancreat Sci. 2019;26:169–78.PubMedCrossRef
13.
Zhang XF, Squires MR, Bagante F, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma. Ann Surg Oncol. 2018;25:1140–9.PubMedCrossRef
14.
Lee J, Kang SH, Noh OK, Chun M, Oh YT, Kim BW, Kim SW. Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma. Clin Transl Oncol. 2018;20:1011–7.PubMedCrossRef
15.
Messina C, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, Salati M, Messina M, Carnaghi C, Caffo O. Adjuvant chemotherapy in resected bile duct cancer: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol. 2019;143:124–9.PubMedCrossRef
16.
Wakai T, Sakata J, Katada T, Hirose Y, Soma D, Prasoon P, Miura K, Kobayashi T. Surgical management of carcinoma in situ at ductal resection margins in patients with extrahepatic cholangiocarcinoma. Ann Gastroenterol Surg. 2018;2:359–66.PubMedPubMedCentralCrossRef
17.
Higuchi R, Yazawa T, Uemura S, Izumo W, Furukawa T, Yamamoto M. High-grade dysplasia/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival: a retrospective study. J Hepatobiliary Pancreat Sci. 2017;24:456–65.PubMedCrossRef
18.
Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Mori S, Kijima Y, Ueno S, Shinchi H, et al. Relationship between the surgical margin status, prognosis, and recurrence in extrahepatic bile duct cancer patients. Langenbecks Arch Surg. 2017;402:87–93.PubMedCrossRef
19.
Tsukahara T, Ebata T, Shimoyama Y, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Nagino M. Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas. Ann Surg. 2017;266:126–32.PubMedCrossRef
20.
Shiraki T, Kuroda H, Takada A, Nakazato Y, Kubota K, Imai Y. Intraoperative frozen section diagnosis of bile duct margin for extrahepatic cholangiocarcinoma. World J Gastroenterol. 2018;24:1332–42.PubMedPubMedCentralCrossRef
21.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedPubMedCentralCrossRef
22.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef
23.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRef
24.
Deeks JJ, Altman DG: Chapter 9. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions Cochrane book 2011.
25.
26.
Li MX, Bi XY, Li ZY, Huang Z, Han Y, Zhao JJ, Zhao H, Cai JQ. Impaction of surgical margin status on the survival outcome after surgical resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Surg Res. 2016;203:163–73.PubMedCrossRef
27.
Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer-Am Cancer Soc. 2005;103:1210–6.
28.
Higuchi R, Ota T, Araida T, Kobayashi M, Furukawa T, Yamamoto M. Prognostic relevance of ductal margins in operative resection of bile duct cancer. Surgery. 2010;148:7–14.PubMedCrossRef
29.
Ueda J, Yoshida H, Mamada Y, Taniai N, Yoshioka M, Hirakata A, Kawano Y, Mizuguchi Y, Shimizu T, Kanda T, et al. Evaluation of positive ductal margins of biliary tract cancer in intraoperative histological examination. Oncol Lett. 2018;16:6677–84.PubMedPubMedCentral
30.
Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, Sugai T, Wakabayashi G, Ohkohchi N. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg. 2007;31:1788–96.PubMedCrossRef
31.
Endo I, House MG, Klimstra DS, Gonen M, D’Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:2104–12.PubMedCrossRef
32.
Igami T, Nagino M, Oda K, Nishio H, Ebata T, Yokoyama Y, Shimoyama Y. Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg. 2009;249:296–302.PubMedCrossRef
33.
Nakanishi Y, Kondo S, Zen Y, Yonemori A, Kubota K, Kawakami H, Tanaka E, Hirano S, Itoh T, Nakanuma Y. Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci. 2010;17:166–73.PubMedCrossRef
34.
Wakai T, Shirai Y, Sakata J, Korita PV, Matsuda Y, Takamura M, Ohashi R, Nagahashi M, Ajioka Y, Hatakeyama K. Alteration of p53-binding protein 1 expression as a risk factor for local recurrence in patients undergoing resection for extrahepatic cholangiocarcinoma. Int J Oncol. 2011;38:1227–36.PubMedCrossRef
35.
Han IW, Jang JY, Lee KB, Kang MJ, Kwon W, Park JW, Chang YR, Kim SW. Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin. HPB (Oxford). 2014;16:575–81.CrossRef
36.
Oguro S, Esaki M, Kishi Y, Nara S, Shimada K, Ojima H, Kosuge T. Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma. Ann Surg Oncol. 2015;22:1915–24.PubMedCrossRef
37.
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–69.PubMedCrossRef
38.
Buettner S, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford). 2016;18:510–7.CrossRef
39.
Mantel HT, Westerkamp AC, Sieders E, Peeters PM, de Jong KP, Boer MT, de Kleine RH, Gouw AS, Porte RJ. Intraoperative frozen section analysis of the proximal bile ducts in hilar cholangiocarcinoma is of limited value. Cancer Med. 2016;5:1373–80.PubMedPubMedCentralCrossRef
40.
Ma WJ, Shrestha A, Li FY. Is intraoperative frozen section analysis of the proximal bile ducts in hilar cholangiocarcinoma of limited value? Cancer Med. 2016;5:2848–9.PubMedPubMedCentralCrossRef
41.
Otsuka S, Ebata T, Yokoyama Y, Mizuno T, Tsukahara T, Shimoyama Y, Ando M, Nagino M. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma. Br J Surg. 2019;106:774–82.PubMedCrossRef
42.
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz M, Primrose J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015–27.PubMedCrossRef
43.
Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, et al. Defining early recurrence of hilar cholangiocarcinoma after curative-intent surgery: a multi-institutional study from the US Extrahepatic Biliary Malignancy Consortium. World J Surg. 2018;42:2919–29.PubMedCrossRef
44.
Groot KB, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D’Angelica MI, DeMatteo RP, Gouma DJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041–9.CrossRef
Metadata
Title
Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis
Authors
Qiao Ke
Bin Wang
Nanping Lin
Lei Wang
Jingfeng Liu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1749-7

Other articles of this Issue 1/2019

World Journal of Surgical Oncology 1/2019 Go to the issue

Review

Role of the intestinal microbiome in colorectal cancer surgery outcomes

Case report

Endometrioid adenocarcinoma of the rectovaginal septum with invasion of the rectum: a case report and review of literature

Research

Endoscopic submucosal dissection for gastric ectopic pancreas: a single-center experience

Research

Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1–2 and cN0 breast cancer

Research

Liver resection for hepatocellular carcinoma in oldest old patients

Research

Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy